China Nuokang Bio-Pharmaceutical Provides Update on Product Pipeline

Shenyang, CHINA


Kaitong Technical Review Completed
Dipyridamole Aspirin Onsite Inspection Completed

Company to Report Second Quarter 2010 Financial Results on August 25, 2010

BEIJING, Aug. 4, 2010 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company"), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that two of its product pipeline candidates recently advanced through the next respective stages of the State Food and Drug Administration ("SFDA") review process. The Company provided the following updates on its key product candidate Kaitong, a product in-licensed from the Company's partner, Jilin Yuhua, and Dipyridamole Aspirin, a product developed internally by Nuokang:

  • Kaitong: Nuokang's development partner for Kaitong, Jilin Yuhua, received a notice from the SFDA to progress to the on-site inspection of its manufacturing facilities. As such, the SFDA has completed its technical review and Kaitong's development is moving forward as planned. Nuokang continues to expect to receive the manufacturing license for Kaitong by the end of 2010.
  • Dipyridamole Aspirin: The SFDA recently completed its onsite inspection, a final step in the SFDA review process. The Company also continues to expect to receive the manufacturing license for Dipyridamole Aspirin by the end of 2010.

BaiZhong Xue, the Company's Chairman and CEO, commented, "We are pleased with today's news that our two product candidates are moving forward as planned. The technical review of Kaitong was completed successfully and we will continue to work closely with Jilin Yuhua to obtain the manufacturing license as expeditiously as possible, with our goal still being to receive the license by the end of this year. Once the license is received, we are well prepared to quickly and effectively launch the product across our distribution network."  

Additionally, the Company plans to release its second quarter 2010 financial results on August 25, 2010, after market close.  The Company will hold a conference call at 8:00 am ET the following morning to discuss financial results.  Listeners may access the call by dialing:

United States toll free: 1-866-788-0542
China toll free:  10-800-7122655
Hong Kong toll free:  800-963844
United Kingdom toll free: 0808-2347616
International: 1-857-350-1680
Conference ID: 50147156

A telephone replay will be available beginning two hours after the conclusion of the call and will be available through September 2, 2010.  Listeners may access the replay by dialing:

United States toll free:  1-888-286-8010
International:  1-617-801-6888
Conference ID: 19232320

A webcast will also be available through the Company's website www.nkbp.com. ;

About China Nuokang Bio-Pharmaceutical Inc.

China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) is a leading biopharmaceutical company in China focused on the research, development, manufacture, marketing and sales of hospital-based medical products.  The Company provides a diversified portfolio of products across more than 2,400 hospitals in China.  Nuokang's principal products include Baquting®, China's leading hemocoagulase product by market share, and Aiduo®, a cardiovascular stress imaging agent. The Company's product pipeline includes product candidates under development in hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention.  Please visit www.nkbp.com for more information. 

Safe-Harbor Statement

This press release contains statements of a forward-looking nature.  These statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including certain plans, expectations, goals, and projections, which are subject to numerous assumptions, risks, and uncertainties.  These forward-looking statements may include, but are not limited to, statements containing words such as "may," "could," "would," "plan," "anticipate," "believe," "estimate," "predict," "potential," "expects," "intends" and "future" or similar expressions.  Among other things, the statements relating to the Company's expected progress on the new product portfolio may contain forward-looking statements.  These forward-looking statements speak only as of the date of this press release and are subject to change at any time.  These forward-looking statements are based upon management's current expectations and are subject to a number of risks, uncertainties and contingencies, many of which are beyond the Company's control that may cause actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements.  The Company's actual results could differ materially from those contained in the forward-looking statements due to a number of factors, including those described under the heading "Risk Factors" in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F.


                    

        

Contact Data